Filing Flows › Comparisons › IVVD vs CRSP
Invivyd vs Crispr Therapeutics AG: IVVD and CRSP compared
Invivyd is the larger company: $14.3M of revenue in its latest quarter (Q2 2026) against $12.7M for Crispr Therapeutics AG (Q3 2026). Crispr Therapeutics AG is growing faster (14× against +21% a year earlier).
Where the money goes: IVVD and CRSP
Invivyd (IVVD) · Q2 2026
Invivyd, Q2 2026: revenue $14.3M (+21% year over year), operating margin -320.8%, net loss $44.4M, operating cash flow −$43.0M. The chart follows the revenue to costs, profit and cash.
Crispr Therapeutics AG (CRSP) · Q3 2026
Crispr Therapeutics AG, Q3 2026: revenue $12.7M (14× year over year), net loss $111M, operating cash flow −$89.7M. The chart follows the revenue to costs, profit and cash.
| Invivyd (IVVD) | Crispr Therapeutics AG (CRSP) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $14.3M | $12.7M |
| Revenue growth, Y/Y | +21% | 14× |
| Operating margin | -320.8% | n/m |
| Net earnings | −$44.4M | −$111M |
| Net margin | -310.8% | -879.6% |
| Operating cash flow | −$43.0M | −$89.7M |
Where the revenue comes from
Crispr Therapeutics AG
- Collaboration Revenue: $12.3M (97%)
- Grant: $346K (3%)
Questions
Which is bigger, Invivyd or Crispr Therapeutics AG?
Invivyd is the larger company: $14.3M of revenue in its latest quarter (Q2 2026) against $12.7M for Crispr Therapeutics AG (Q3 2026).
Is Invivyd or Crispr Therapeutics AG growing faster?
Crispr Therapeutics AG is growing faster (14× against +21% a year earlier).
More: Invivyd earnings · how Invivyd makes money · Crispr Therapeutics AG earnings · how Crispr Therapeutics AG makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Nov 2, 2026). Fiscal quarters can end on different dates. Not investment advice.